U.S. Markets open in 3 hrs 18 mins
  • S&P Futures

    3,418.50
    -14.00 (-0.41%)
     
  • Dow Futures

    28,020.00
    -114.00 (-0.41%)
     
  • Nasdaq Futures

    11,638.75
    -52.50 (-0.45%)
     
  • Russell 2000 Futures

    1,601.00
    -2.10 (-0.13%)
     
  • Crude Oil

    40.10
    +0.07 (+0.17%)
     
  • Gold

    1,919.50
    -10.00 (-0.52%)
     
  • Silver

    24.92
    -0.33 (-1.29%)
     
  • EUR/USD

    1.1832
    -0.0035 (-0.2958%)
     
  • 10-Yr Bond

    0.8160
    0.0000 (0.00%)
     
  • Vix

    29.35
    0.00 (0.00%)
     
  • GBP/USD

    1.3096
    -0.0048 (-0.3628%)
     
  • USD/JPY

    104.7390
    +0.1790 (+0.1712%)
     
  • BTC-USD

    12,870.82
    +1,813.82 (+16.40%)
     
  • CMC Crypto 200

    258.05
    +13.16 (+5.37%)
     
  • FTSE 100

    5,759.17
    -17.33 (-0.30%)
     
  • Nikkei 225

    23,474.27
    -92.73 (-0.39%)
     

Benzinga Pro's Top 5 Stocks To Watch For Thurs., Dec. 19, 2019: NKE, TIVO, CBIO, APOG, RAD

Benzinga Newsdesk

Benzinga Pro's Stocks To Watch For Thursday

  • NIKE (NKE) - Shares were up 0.4% premarket ahead of earnings from the company after hours Thursday. Analysts expect NIKE to report around $0.58 in quarterly EPS on sales of just over $10 billion. The stock has been up 13% since the company's last quarterly report in September.

  • TiVo (TIVO) - The company reported it will merge with Xperi (XPER) in a $3 billion deal. TiVo shareholders will own 53.5% of the combined company. While TiVo shares were up about 5%, shares of Xperi were down about 11% on the news.

  • Catalyst Biosciences (CBIO) - The stock was up nearly 30% following news of a license and collaboration deal with Biogen (BIIB) for a dry age-related macular degeneration treatment. The company will receive a $15 million upfront payment and be eligible for an added $340 million in milestones.

  • Apogee (APOG) - Reported a Q3 miss and cut its FY20 EPS guidance. Shares were down about 15%.

  • Rite Aid (RAD) - Shares were up nearly 30% following a Q3 sales beat and better-than-expected FY20 guidance.

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.